A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer
A phase 2 trial of AK117 in triple-negative breast cancer, run by Akeso, active and no longer recruiting.
Overview
A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer is a phase 2 interventional study registered as NCT05227664 by Akeso, with 120 participants enrolled, started 2022-03-23 and due to reach its primary completion in 2026-12-30. Interventions recorded: AK117, AK112, Nab paclitaxel and paclitaxel.
Setting
A Phase II Study of AK117/AK112 in Combination With Chemotherapy for Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer
Phase
Phase 2
Sponsor
Akeso
Registry
Enrolled
120
Similar pages
not linked directly; found by shared links- TrialA Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia
- TrialA Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors
- TrialA Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors
Shares Akeso and the tag pipeline.
- TrialA Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors
Shares Akeso and the tag pipeline.
- TrialA Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer
Shares Akeso and the tag pipeline.
- TrialA Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer
Shares Akeso and the tag pipeline.
- TrialProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialA Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.